Global Tetrabenazine Market
Global Tetrabenazine Market

Tetrabenazine Comprehensive Study by Application (Hospital Dispensaries, Retail Pharmacies, Online Third-Party Websites), Indication (Huntington's Disease, Tourette Syndrome and Tic Disorders, Tardive Dyskinesia), Distribution Channel (Hospital Dispensaries, Retail Pharmacies, Online Third-Party Websites), Packaging (Blister, Bottle) Players and Region - Global Market Outlook to 2026

Tetrabenazine Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 250 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Tetrabenazine Market Scope
Huntington's disease (HD) is a neurodegenerative condition characterized by chorea and other hyperkinetic action disturbances. These, as well as neurological and neurobehavioral symptoms, all play a role in the patient's impairment. To treat the different effects of HD, a variety of drug types are used the most common of which is Tetrabenazine. TBZ has been shown to be helpful in a variety of other disorders, including tardive dyskinesia, dystonia, tics, and Tourette's syndrome, according to some clinical reviews undertaken by several scientific organizations.

The Tetrabenazine market study is segmented, by Application (Hospital Dispensaries, Retail Pharmacies and Online Third-Party Websites) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.

Biovail Corporation (Canada), Cambridge Laboratories Ltd (United States), Teva Pharmaceutical Industries Ltd. (Israel), Hetero Labs Limited (India), Sun Pharmaceutical Industries Ltd. (India), Bionpharma Inc. (United States), Camber Pharmaceuticals Inc (United States), Intas Biopharmaceuticals (India), Lupin Limited (India) and Dr. Reddy's Laboratories (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Oceanside Pharmaceuticals Inc. (United States), Lundbeck (Denmark), Hikma Pharmaceuticals plc (United Kingdom) and Apotex Inc. (Canada).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Tetrabenazine market by Type, Application and Region.

On the basis of geography, the market of Tetrabenazine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 13th September, 2019 - Hikma launched Tetrabenazine Tablets, 12.5mg and 25mg, the Generic Equivalent to Xenazine. The Tetrabenazine Tablets Are A Vesicular Monoamine Transporter 2 (VMAT) Receptor Indicated to Treat Chorea Caused by Huntington's Disease. and On 15th April, 2021 - Teva Pharmaceuticals Announced the Launch of its New Analyses of “AJOVY (fremanezumab-vfrm)” Injection and “AUSTEDO” (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting Aiming to Strengthen its Position Across Neurology Market.


Market Trend
  • Growing Pharmaceutical Infrastructure

Market Drivers
  • Prevalence of Tourette Syndrome and Tic Disorders
  • High Research & Development in Pharmaceutical industry

Opportunities
  • Rising penetration Across Emerging Regions

Restraints
  • Lack of Trained Professionals
  • Drug Abuse and Adverse Reactions

Challenges
  • Skewed player Distribution


Key Target Audience
Tetrabenazine Products Manufactures, New Entrants and Investors, API Providers, Tetrabenazine Products Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Tetrabenazine Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Application
  • Hospital Dispensaries
  • Retail Pharmacies
  • Online Third-Party Websites
By Indication
  • Huntington's Disease
  • Tourette Syndrome and Tic Disorders
  • Tardive Dyskinesia

By Distribution Channel
  • Hospital Dispensaries
  • Retail Pharmacies
  • Online Third-Party Websites

By Packaging
  • Blister
  • Bottle

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Tourette Syndrome and Tic Disorders
      • 3.2.2. High Research & Development in Pharmaceutical industry
    • 3.3. Market Challenges
      • 3.3.1. Skewed player Distribution
    • 3.4. Market Trends
      • 3.4.1. Growing Pharmaceutical Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tetrabenazine, by Application, Indication, Distribution Channel, Packaging and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Tetrabenazine (Value)
      • 5.2.1. Global Tetrabenazine by: Application (Value)
        • 5.2.1.1. Hospital Dispensaries
        • 5.2.1.2. Retail Pharmacies
        • 5.2.1.3. Online Third-Party Websites
      • 5.2.2. Global Tetrabenazine by: Indication (Value)
        • 5.2.2.1. Huntington's Disease
        • 5.2.2.2. Tourette Syndrome and Tic Disorders
        • 5.2.2.3. Tardive Dyskinesia
      • 5.2.3. Global Tetrabenazine by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Dispensaries
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Third-Party Websites
      • 5.2.4. Global Tetrabenazine by: Packaging (Value)
        • 5.2.4.1. Blister
        • 5.2.4.2. Bottle
      • 5.2.5. Global Tetrabenazine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Tetrabenazine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biovail Corporation (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cambridge Laboratories Ltd (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hetero Labs Limited (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bionpharma Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Camber Pharmaceuticals Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Intas Biopharmaceuticals (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lupin Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dr. Reddy's Laboratories (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tetrabenazine Sale, by Application, Indication, Distribution Channel, Packaging and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Tetrabenazine (Value)
      • 7.2.1. Global Tetrabenazine by: Application (Value)
        • 7.2.1.1. Hospital Dispensaries
        • 7.2.1.2. Retail Pharmacies
        • 7.2.1.3. Online Third-Party Websites
      • 7.2.2. Global Tetrabenazine by: Indication (Value)
        • 7.2.2.1. Huntington's Disease
        • 7.2.2.2. Tourette Syndrome and Tic Disorders
        • 7.2.2.3. Tardive Dyskinesia
      • 7.2.3. Global Tetrabenazine by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Dispensaries
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Third-Party Websites
      • 7.2.4. Global Tetrabenazine by: Packaging (Value)
        • 7.2.4.1. Blister
        • 7.2.4.2. Bottle
      • 7.2.5. Global Tetrabenazine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tetrabenazine: by Application(USD Million)
  • Table 2. Tetrabenazine Hospital Dispensaries , by Region USD Million (2015-2020)
  • Table 3. Tetrabenazine Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 4. Tetrabenazine Online Third-Party Websites , by Region USD Million (2015-2020)
  • Table 5. Tetrabenazine: by Indication(USD Million)
  • Table 6. Tetrabenazine Huntington's Disease , by Region USD Million (2015-2020)
  • Table 7. Tetrabenazine Tourette Syndrome and Tic Disorders , by Region USD Million (2015-2020)
  • Table 8. Tetrabenazine Tardive Dyskinesia , by Region USD Million (2015-2020)
  • Table 9. Tetrabenazine: by Distribution Channel(USD Million)
  • Table 10. Tetrabenazine Hospital Dispensaries , by Region USD Million (2015-2020)
  • Table 11. Tetrabenazine Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Tetrabenazine Online Third-Party Websites , by Region USD Million (2015-2020)
  • Table 13. Tetrabenazine: by Packaging(USD Million)
  • Table 14. Tetrabenazine Blister , by Region USD Million (2015-2020)
  • Table 15. Tetrabenazine Bottle , by Region USD Million (2015-2020)
  • Table 16. South America Tetrabenazine, by Country USD Million (2015-2020)
  • Table 17. South America Tetrabenazine, by Application USD Million (2015-2020)
  • Table 18. South America Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 19. South America Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 20. South America Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 21. Brazil Tetrabenazine, by Application USD Million (2015-2020)
  • Table 22. Brazil Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 23. Brazil Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 24. Brazil Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 25. Argentina Tetrabenazine, by Application USD Million (2015-2020)
  • Table 26. Argentina Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 27. Argentina Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 28. Argentina Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 29. Rest of South America Tetrabenazine, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 31. Rest of South America Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 32. Rest of South America Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 33. Asia Pacific Tetrabenazine, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Tetrabenazine, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 36. Asia Pacific Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 37. Asia Pacific Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 38. China Tetrabenazine, by Application USD Million (2015-2020)
  • Table 39. China Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 40. China Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 41. China Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 42. Japan Tetrabenazine, by Application USD Million (2015-2020)
  • Table 43. Japan Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 44. Japan Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 45. Japan Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 46. India Tetrabenazine, by Application USD Million (2015-2020)
  • Table 47. India Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 48. India Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 49. India Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 50. South Korea Tetrabenazine, by Application USD Million (2015-2020)
  • Table 51. South Korea Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 52. South Korea Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 53. South Korea Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 54. Taiwan Tetrabenazine, by Application USD Million (2015-2020)
  • Table 55. Taiwan Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 56. Taiwan Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 57. Taiwan Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 58. Australia Tetrabenazine, by Application USD Million (2015-2020)
  • Table 59. Australia Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 60. Australia Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 61. Australia Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Tetrabenazine, by Application USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 66. Europe Tetrabenazine, by Country USD Million (2015-2020)
  • Table 67. Europe Tetrabenazine, by Application USD Million (2015-2020)
  • Table 68. Europe Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 69. Europe Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 70. Europe Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 71. Germany Tetrabenazine, by Application USD Million (2015-2020)
  • Table 72. Germany Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 73. Germany Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 74. Germany Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 75. France Tetrabenazine, by Application USD Million (2015-2020)
  • Table 76. France Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 77. France Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 78. France Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 79. Italy Tetrabenazine, by Application USD Million (2015-2020)
  • Table 80. Italy Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 81. Italy Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 82. Italy Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 83. United Kingdom Tetrabenazine, by Application USD Million (2015-2020)
  • Table 84. United Kingdom Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 85. United Kingdom Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 86. United Kingdom Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 87. Netherlands Tetrabenazine, by Application USD Million (2015-2020)
  • Table 88. Netherlands Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 89. Netherlands Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 90. Netherlands Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 91. Rest of Europe Tetrabenazine, by Application USD Million (2015-2020)
  • Table 92. Rest of Europe Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 93. Rest of Europe Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 94. Rest of Europe Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 95. MEA Tetrabenazine, by Country USD Million (2015-2020)
  • Table 96. MEA Tetrabenazine, by Application USD Million (2015-2020)
  • Table 97. MEA Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 98. MEA Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 99. MEA Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 100. Middle East Tetrabenazine, by Application USD Million (2015-2020)
  • Table 101. Middle East Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 102. Middle East Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 103. Middle East Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 104. Africa Tetrabenazine, by Application USD Million (2015-2020)
  • Table 105. Africa Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 106. Africa Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 107. Africa Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 108. North America Tetrabenazine, by Country USD Million (2015-2020)
  • Table 109. North America Tetrabenazine, by Application USD Million (2015-2020)
  • Table 110. North America Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 111. North America Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 112. North America Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 113. United States Tetrabenazine, by Application USD Million (2015-2020)
  • Table 114. United States Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 115. United States Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 116. United States Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 117. Canada Tetrabenazine, by Application USD Million (2015-2020)
  • Table 118. Canada Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 119. Canada Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 120. Canada Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 121. Mexico Tetrabenazine, by Application USD Million (2015-2020)
  • Table 122. Mexico Tetrabenazine, by Indication USD Million (2015-2020)
  • Table 123. Mexico Tetrabenazine, by Distribution Channel USD Million (2015-2020)
  • Table 124. Mexico Tetrabenazine, by Packaging USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Tetrabenazine: by Application(USD Million)
  • Table 136. Tetrabenazine Hospital Dispensaries , by Region USD Million (2021-2026)
  • Table 137. Tetrabenazine Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 138. Tetrabenazine Online Third-Party Websites , by Region USD Million (2021-2026)
  • Table 139. Tetrabenazine: by Indication(USD Million)
  • Table 140. Tetrabenazine Huntington's Disease , by Region USD Million (2021-2026)
  • Table 141. Tetrabenazine Tourette Syndrome and Tic Disorders , by Region USD Million (2021-2026)
  • Table 142. Tetrabenazine Tardive Dyskinesia , by Region USD Million (2021-2026)
  • Table 143. Tetrabenazine: by Distribution Channel(USD Million)
  • Table 144. Tetrabenazine Hospital Dispensaries , by Region USD Million (2021-2026)
  • Table 145. Tetrabenazine Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 146. Tetrabenazine Online Third-Party Websites , by Region USD Million (2021-2026)
  • Table 147. Tetrabenazine: by Packaging(USD Million)
  • Table 148. Tetrabenazine Blister , by Region USD Million (2021-2026)
  • Table 149. Tetrabenazine Bottle , by Region USD Million (2021-2026)
  • Table 150. South America Tetrabenazine, by Country USD Million (2021-2026)
  • Table 151. South America Tetrabenazine, by Application USD Million (2021-2026)
  • Table 152. South America Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 153. South America Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 154. South America Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 155. Brazil Tetrabenazine, by Application USD Million (2021-2026)
  • Table 156. Brazil Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 157. Brazil Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 158. Brazil Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 159. Argentina Tetrabenazine, by Application USD Million (2021-2026)
  • Table 160. Argentina Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 161. Argentina Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 162. Argentina Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 163. Rest of South America Tetrabenazine, by Application USD Million (2021-2026)
  • Table 164. Rest of South America Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 165. Rest of South America Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 166. Rest of South America Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 167. Asia Pacific Tetrabenazine, by Country USD Million (2021-2026)
  • Table 168. Asia Pacific Tetrabenazine, by Application USD Million (2021-2026)
  • Table 169. Asia Pacific Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 170. Asia Pacific Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 171. Asia Pacific Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 172. China Tetrabenazine, by Application USD Million (2021-2026)
  • Table 173. China Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 174. China Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 175. China Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 176. Japan Tetrabenazine, by Application USD Million (2021-2026)
  • Table 177. Japan Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 178. Japan Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 179. Japan Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 180. India Tetrabenazine, by Application USD Million (2021-2026)
  • Table 181. India Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 182. India Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 183. India Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 184. South Korea Tetrabenazine, by Application USD Million (2021-2026)
  • Table 185. South Korea Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 186. South Korea Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 187. South Korea Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 188. Taiwan Tetrabenazine, by Application USD Million (2021-2026)
  • Table 189. Taiwan Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 190. Taiwan Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 191. Taiwan Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 192. Australia Tetrabenazine, by Application USD Million (2021-2026)
  • Table 193. Australia Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 194. Australia Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 195. Australia Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Tetrabenazine, by Application USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 200. Europe Tetrabenazine, by Country USD Million (2021-2026)
  • Table 201. Europe Tetrabenazine, by Application USD Million (2021-2026)
  • Table 202. Europe Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 203. Europe Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 204. Europe Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 205. Germany Tetrabenazine, by Application USD Million (2021-2026)
  • Table 206. Germany Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 207. Germany Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 208. Germany Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 209. France Tetrabenazine, by Application USD Million (2021-2026)
  • Table 210. France Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 211. France Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 212. France Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 213. Italy Tetrabenazine, by Application USD Million (2021-2026)
  • Table 214. Italy Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 215. Italy Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 216. Italy Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 217. United Kingdom Tetrabenazine, by Application USD Million (2021-2026)
  • Table 218. United Kingdom Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 219. United Kingdom Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 220. United Kingdom Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 221. Netherlands Tetrabenazine, by Application USD Million (2021-2026)
  • Table 222. Netherlands Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 223. Netherlands Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 224. Netherlands Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 225. Rest of Europe Tetrabenazine, by Application USD Million (2021-2026)
  • Table 226. Rest of Europe Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 227. Rest of Europe Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 228. Rest of Europe Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 229. MEA Tetrabenazine, by Country USD Million (2021-2026)
  • Table 230. MEA Tetrabenazine, by Application USD Million (2021-2026)
  • Table 231. MEA Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 232. MEA Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 233. MEA Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 234. Middle East Tetrabenazine, by Application USD Million (2021-2026)
  • Table 235. Middle East Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 236. Middle East Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 237. Middle East Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 238. Africa Tetrabenazine, by Application USD Million (2021-2026)
  • Table 239. Africa Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 240. Africa Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 241. Africa Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 242. North America Tetrabenazine, by Country USD Million (2021-2026)
  • Table 243. North America Tetrabenazine, by Application USD Million (2021-2026)
  • Table 244. North America Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 245. North America Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 246. North America Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 247. United States Tetrabenazine, by Application USD Million (2021-2026)
  • Table 248. United States Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 249. United States Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 250. United States Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 251. Canada Tetrabenazine, by Application USD Million (2021-2026)
  • Table 252. Canada Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 253. Canada Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 254. Canada Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 255. Mexico Tetrabenazine, by Application USD Million (2021-2026)
  • Table 256. Mexico Tetrabenazine, by Indication USD Million (2021-2026)
  • Table 257. Mexico Tetrabenazine, by Distribution Channel USD Million (2021-2026)
  • Table 258. Mexico Tetrabenazine, by Packaging USD Million (2021-2026)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tetrabenazine: by Application USD Million (2015-2020)
  • Figure 5. Global Tetrabenazine: by Indication USD Million (2015-2020)
  • Figure 6. Global Tetrabenazine: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Tetrabenazine: by Packaging USD Million (2015-2020)
  • Figure 8. South America Tetrabenazine Share (%), by Country
  • Figure 9. Asia Pacific Tetrabenazine Share (%), by Country
  • Figure 10. Europe Tetrabenazine Share (%), by Country
  • Figure 11. MEA Tetrabenazine Share (%), by Country
  • Figure 12. North America Tetrabenazine Share (%), by Country
  • Figure 13. Global Tetrabenazine share by Players 2020 (%)
  • Figure 14. Global Tetrabenazine share by Players (Top 3) 2020(%)
  • Figure 15. Global Tetrabenazine share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Biovail Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 18. Biovail Corporation (Canada) Revenue: by Geography 2020
  • Figure 19. Cambridge Laboratories Ltd (United States) Revenue, Net Income and Gross profit
  • Figure 20. Cambridge Laboratories Ltd (United States) Revenue: by Geography 2020
  • Figure 21. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 23. Hetero Labs Limited (India) Revenue, Net Income and Gross profit
  • Figure 24. Hetero Labs Limited (India) Revenue: by Geography 2020
  • Figure 25. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 26. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2020
  • Figure 27. Bionpharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Bionpharma Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Camber Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Camber Pharmaceuticals Inc (United States) Revenue: by Geography 2020
  • Figure 31. Intas Biopharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 32. Intas Biopharmaceuticals (India) Revenue: by Geography 2020
  • Figure 33. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Lupin Limited (India) Revenue: by Geography 2020
  • Figure 35. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 36. Dr. Reddy's Laboratories (India) Revenue: by Geography 2020
  • Figure 37. Global Tetrabenazine: by Application USD Million (2021-2026)
  • Figure 38. Global Tetrabenazine: by Indication USD Million (2021-2026)
  • Figure 39. Global Tetrabenazine: by Distribution Channel USD Million (2021-2026)
  • Figure 40. Global Tetrabenazine: by Packaging USD Million (2021-2026)
  • Figure 41. South America Tetrabenazine Share (%), by Country
  • Figure 42. Asia Pacific Tetrabenazine Share (%), by Country
  • Figure 43. Europe Tetrabenazine Share (%), by Country
  • Figure 44. MEA Tetrabenazine Share (%), by Country
  • Figure 45. North America Tetrabenazine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Biovail Corporation (Canada)
  • Cambridge Laboratories Ltd (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Hetero Labs Limited (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Bionpharma Inc. (United States)
  • Camber Pharmaceuticals Inc (United States)
  • Intas Biopharmaceuticals (India)
  • Lupin Limited (India)
  • Dr. Reddy's Laboratories (India)
Additional players considered in the study are as follows:
Oceanside Pharmaceuticals Inc. (United States) , Lundbeck (Denmark) , Hikma Pharmaceuticals plc (United Kingdom) , Apotex Inc. (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation